Cost Analysis of Commonly used Combination of Drugs in Primary Open Angle Glaucoma

Kumbar, Shivaprasad Kalakappa; Mirje, Mrutyunjay; Moharir, Gurudatta; Bharatha, Ambadasu

doi:10.7860/jcdr/2015/12491.5966

Cited by 4 publications

(8 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cost effectiveness was calculated by dividing the drug cost by the degree of the IOP reduction (mmHg), which is considered the efficacy of the drug, over the course of the study period [ 14 ]. The price per day of each drug multiplied by the number of days studied equals the drug cost during the study.…”

Section: Methodsmentioning

confidence: 99%

Daily Costs and Cost Effectiveness of Glaucoma Fixed Combinations in China

Guo

Huang

et al. 2020

Journal of Ophthalmology

View full text Add to dashboard Cite

Background. The aim of this study was to compare the daily costs and cost effectiveness of fixed combination glaucoma drugs in China. Methods. This study included the following fixed combination drugs: brinzolamide 1% and timolol 0.5% (Azarga; Alcon, Inc., Fort Worth, TX, USA), travoprost 0.004% and timolol 0.5% (DuoTrav; Alcon, Inc.), bimatoprost 0.03% and timolol 0.5% (Ganfort; Allergan, Inc., Dublin, Ireland), and latanoprost 0.005% and timolol 0.5% (Xalacom; Pfizer, Inc., New York, NY, USA). Five bottles of each drug were measured. The mean actual volume, mean actual number of drops, volume per drop, daily cost, yearly cost, and per mmHg reduction cost for each drug were calculated. Results. The volumes per drop ranged from 32.61 ± 2.90 μl (DuoTrav) to 24.38 ± 0.23 μl (Ganfort). The number of usage days per bottle varied from 36 days (DuoTrav) to 61 days (Ganfort). Azarga had the lowest daily cost ($0.23) and yearly cost ($84.72), while DuoTrav had the highest daily cost ($0.79) and yearly cost ($287.02). Azarga costed $2.17–$3.30 per mmHg intraocular pressure reduction, which was lower than the other three drugs. For the prostaglandin and ß-adrenergic blocker FCs, Ganfort had the lowest daily cost ($0.35) and per mmHg reduction cost (from $3.40 to $4.04). Conclusions. The daily costs of these drugs were significantly different, with Azarga having the lowest daily cost and best cost effectiveness. For the prostaglandin and β-adrenergic blocker fixed combinations, Ganfort was the most economical choice with its lower daily cost and per mmHg reduction cost. The results of this study could provide drug selection guidance from an economic perspective, but various factors should be considered when making a decision.

show abstract

Section: Methodsmentioning

confidence: 99%

Daily Costs and Cost Effectiveness of Glaucoma Fixed Combinations in China

Guo

Huang

et al. 2020

Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…An Indian study compared three drug combinations, and found that the combination of Brimonidine/Timolol was most cost effective. They calculated cost-effectiveness by cost per mm IOP reduction [14].…”

Section: Resultsmentioning

confidence: 99%

“…Combinations of Dorzolamide plus Timolol, Brimonidine plus Timolol, and Latanoprost plus Timolol were compared. Brimonidine plus Timolol was found to be most cost effective among three groups [14].…”

Section: Fixed-combination Drugsmentioning

confidence: 94%

See 1 more Smart Citation

Increasing healthcare costs

Töteberg‐Harms

Berlin

Meier-Gibbons

2017

Current Opinion in Ophthalmology

View full text Add to dashboard Cite

It is challenging to find reliable studies concerning this subject matter. As patients are under the umbrellas of variously organized healthcare systems which span different cultures, the costs between countries are difficult to compare. However, one common aspect to lower costs in glaucoma care is to improve patient adherence. Theoretical models with actual patient studies could enable cost reductions by comparing multiple diagnostic and therapeutic scenarios. VIDEO ABSTRACT: http://links.lww.com/COOP/A22.

show abstract

“…2 It has been shown that patients with glaucoma who do not receive adequate treatment have a chronic and progressive damage at the level of the optic nerve, which leads quickly and inexorably to blindness. 3 Glaucoma is the second cause of blindness in the world 4 and the first when it comes to irreversible blindness. 5…”

Section: Introductionmentioning

confidence: 99%

Direct costs of glaucoma: Relationship between cost and severity of the disease

et al. 2018

View full text Add to dashboard Cite

Objectives To estimate the direct medical costs associated with the management of patients with primary open-angle glaucoma and to compare the costs of patients according to the degree of severity. Methods A longitudinal retrospective study was carried out using all patients with primary open-angle glaucoma that recorded follow-up from May 2010 to June 2013 at the Hospital Privado de Córdoba. We estimated the cost of the disease from the perspectives of the institution, with a bottom-up approach. Results The three-year follow-up after treatment of 104 patients revealed that the average cost of care for a patient with primary open-angle glaucoma was US$2746 ± 1560. The first year of treatment was significantly more expensive than subsequent ones (US$1100–$810–$827). Cost was related to the degree of severity of glaucoma; patients in “Stage 0” had significantly lower costs than those in other groups (Kruskal–Wallis test, p < 0.01). This was a consequence of lower costs associated with medication and a lower percentage of patients undergoing surgery. Discussion The direct medical costs of a patient with primary open-angle glaucoma vary according to the severity of their disease and the year of treatment. We found that costs increased with disease severity, but decreased over time.

show abstract

Cost Analysis of Commonly used Combination of Drugs in Primary Open Angle Glaucoma

Cited by 4 publications

References 22 publications

Daily Costs and Cost Effectiveness of Glaucoma Fixed Combinations in China

Daily Costs and Cost Effectiveness of Glaucoma Fixed Combinations in China

Increasing healthcare costs

Direct costs of glaucoma: Relationship between cost and severity of the disease

Contact Info

Product

Resources

About